COREZOID, INC. – Trademark Portfolio
Entity Type: 03
COREZOID, INC. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 5 trademarks are registered and 2 are pending. Notable registered marks include COREZOID, TRIGGERCARDS, TRIGGER.CARDS, COREZOID ACTOR ENGINE, and COREZOID FROM API TO KPI. The owner is based in Claymont, DE.
2093 Philadelphia Pike, #2235
Claymont, DE 19703
Showing of trademarks Trademarks
Trademark Classifications
COREZOID, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does COREZOID, INC. have?
COREZOID, INC. has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 2 pending, 1 abandoned, 3 cancelled.
What trademark classes does COREZOID, INC. file in?
COREZOID, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are COREZOID, INC.'s most well-known trademarks?
COREZOID, INC.'s registered trademark portfolio includes well-known marks such as COREZOID, TRIGGERCARDS, TRIGGER.CARDS, COREZOID ACTOR ENGINE, and COREZOID FROM API TO KPI. These are among 5 currently registered trademarks in the portfolio.
What is COREZOID, INC.'s trademark registration success rate?
COREZOID, INC. has a 56% trademark registration rate, with 5 out of 9 resolved applications resulting in successful registration. Currently, 2 applications are pending review.